









Markets
/
Stocks
/
nasdaq-arct
/

Arcturus Therapeutics Holdings Inc

ARCT

7.570USD

+0.550+7.83%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

206.17MMarket Cap

LossP/E TTM



Arcturus Therapeutics Holdings Inc

7.570

+0.550+7.83%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Arcturus Therapeutics Holdings Inc

Currency: USD Updated: 2026-02-06

Key Insights

Arcturus Therapeutics Holdings Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 62 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.70.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Arcturus Therapeutics Holdings Inc's Score

Industry at a Glance

Industry Ranking

62 / 392

Overall Ranking

181 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Arcturus Therapeutics Holdings Inc Highlights

StrengthsRisks

Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.

Fairly Valued

The company’s latest PE is -3.08, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 24.41M shares, increasing 0.27% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 14.26K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.56.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

34.700

Target Price

+394.30%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Arcturus Therapeutics Holdings Inc is 8.06, ranking 64 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 17.15M, representing a year-over-year decrease of 58.84%, while its net profit experienced a year-over-year decrease of 94.81%.

Score

Industry at a Glance

Previous score

8.06

Change



Financials

9.43

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.07

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.58

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.19

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Arcturus Therapeutics Holdings Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Arcturus Therapeutics Holdings Inc is 7.11, ranking 173 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.08, which is -2207.16% below the recent high of 64.80 and -1152.22% above the recent low of -38.51.

Score

Industry at a Glance

Previous score

7.11

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 62/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Arcturus Therapeutics Holdings Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 21.50, with a high of 68.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

34.700

Target Price

+373.40%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Arcturus Therapeutics Holdings Inc

ARCT

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Arcturus Therapeutics Holdings Inc is 6.03, ranking 284 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 8.11 and the support level at 6.86, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.62

Change

0.41

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.003

Buy

RSI(14)

55.427

Neutral

STOCH(KDJ)(9,3,3)

37.535

Buy

ATR(14)

0.422

High Vlolatility

CCI(14)

6.627

Neutral

Williams %R

38.000

Buy

TRIX(12,20)

0.323

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

7.322

Buy

MA10

7.384

Buy

MA20

7.392

Buy

MA50

6.994

Buy

MA100

10.895

Sell

MA200

12.416

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Arcturus Therapeutics Holdings Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 101.05%, representing a quarter-over-quarter decrease of 4.62%. The largest institutional shareholder is Catherine Wood, holding a total of 2.61M shares, representing 9.19% of shares outstanding, with 24.09% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Federated Hermes Global Investment Management Corp.

4.69M

ARK Investment Management LLC

Star Investors

1.87M

+9.19%

BlackRock Institutional Trust Company, N.A.

2.10M

-1.86%

The Vanguard Group, Inc.

Star Investors

1.89M

+4.17%

Amova Asset Management Co., Ltd.

1.95M

+6.30%

Payne (Joseph E)

1.48M

State Street Investment Management (US)

1.05M

+2.54%

Balyasny Asset Management LP

964.99K

+11.68%

Morgan Stanley & Co. LLC

695.85K

+16.95%

Schonfeld Strategic Advisors LLC

667.83K

-14.86%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Arcturus Therapeutics Holdings Inc is 2.19, ranking 247 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.43. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.